Abiopharma

🔍 Garland J. Scott (Executive)

Company: Enliven Therapeutics, Inc. (ELVN)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 59,372 shares of Stock Option (right to buy) at $15.47 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2036-01-07 | equity_swap_involved: 0 | shares_owned_after: 59,372.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: 1/36th of the shares subject to the option will vest on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.